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Abstract
Background: Adverse consequences of medical interventions are a source of concern, but clinical trials may lack
power to detect elevated rates of such events, while observational studies have inherent limitations. Meta-analysis
allows the combination of individual studies, which can increase power and provide stronger evidence relating to
adverse events. However, meta-analysis of adverse events has associated methodological challenges. The aim of this
study was to systematically identify and review the methodology used in meta-analyses where a primary outcome is
an adverse or unintended event, following a therapeutic intervention.
Methods: Using a collection of reviews identiﬁed previously, 166 references including a meta-analysis were selected
for review. At least one of the primary outcomes in each review was an adverse or unintended event. The nature of
the intervention, source of funding, number of individual meta-analyses performed, number of primary studies
included in the review, and use of meta-analytic methods were all recorded. Speciﬁc areas of interest relating to the
methods used included the choice of outcome metric, methods of dealing with sparse events, heterogeneity,
publication bias and use of individual patient data.
Results: The 166 included reviews were published between 1994 and 2006. Interventions included drugs and
surgery among other interventions. Many of the references being reviewed included multiple meta-analyses with
44.6% (74/166) including more than ten. Randomised trials only were included in 42.2% of meta-analyses (70/166),
observational studies only in 33.7% (56/166) and a mix of observational studies and trials in 15.7% (26/166). Sparse
data, in the form of zero events in one or both arms where the outcome was a count of events, was found in 64
reviews of two-arm studies, of which 41 (64.1%) had zero events in both arms.
Conclusions: Meta-analyses of adverse events data are common and useful in terms of increasing the power to
detect an association with an intervention, especially when the events are infrequent. However, with regard to
existing meta-analyses, a wide variety of diﬀerent methods have been employed, often with no evident rationale for
using a particular approach. More speciﬁcally, the approach to dealing with zero events varies, and guidelines on this
issue would be desirable.
Background
There is increasing concern regarding adverse outcomes
of therapeutic interventions, which may be addressed by
bringing together evidence frommultiple sources [1]. The
Cochrane Collaboration, in its remit to undertake sys-
tematic reviews, has considered adverse events as an area
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worthy of consideration as a deﬁned clinical area that
requires speciﬁc methodology [2], but the emphasis was
placed on the non-statistical elements, such as choice
of outcomes, study types and search strategies. The use
of quantitative evidence synthesis methods with adverse
events speciﬁcally in mind has been considered some
time ago [3], but there is little empirical information col-
lated on meta-analytic approaches within adverse event
meta-analyses.
A recent review of systematic reviews of adverse events
in response to drug interventions included 43 review
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articles published in 2006 [4]. However, the statistical
methods could only be reviewed in the 24 of these that
included a meta-analysis. This review also considered the
search strategies used in the systematic reviews of adverse
events, and this ﬁeld has been better documented since it
is the focus of several further studies [5-9].
The aim of this current systematic review is to inves-
tigate the meta-analytic methodology used where the
primary outcome of the meta-analysis was an adverse
or unintended event, with the aims of identifying which
methods have been used and the challenges faced by
authors. A wide range of therapeutic interventions are
considered, including drugs, surgical procedures, devices,
vaccinations, dietary interventions, anaesthetics and pub-
lic health programmes. It is hoped that this review will
assist in development and standardisation of methods
in future and we discuss the areas of priority for fur-
ther research to facilitate the development of guide-
lines to support meta-analysis of adverse and unintended
outcomes data.
Methods
The dataset of meta-analyses for this current survey was
identiﬁed using a database of systematic reviews collected
previously [7]. The aim of this previous study was to
develop and evaluate search strategies for the retrieval of
systematic reviews, which may or may not include a meta-
analysis, where the primary outcome was an adverse event
(or unintended but positive event) resulting from a clinical
intervention. The databases searched (both electronically
and by hand) in the previous study were the Database of
Abstracts of Reviews of Eﬀects (DARE) and the Cochrane
Database of Systematic Reviews (CDSR). Details of the
search strategy have been described [7].
These search strategies yielded a total of 257 systematic
reviews (246 from DARE plus 11 Cochrane reviews),
published between 1994 and 2006. The initial searches
were updated, yielding a further 20 systematic reviews on
adverse events [9], producing 277 in total.
From the systematic reviews above, references were
selected for inclusion in the current review according to
the following criteria:
1. some form of quantitative synthesis (or test for
heterogeneity with intention to perform a
quantitative synthesis if appropriate) must be
performed using more than one observed estimate of
eﬀect;
2. the study group of interest must have received some
form of clinical intervention with intended or
potential therapeutic eﬀect; and
3. the full study report must be available in English.
A quantitative data synthesis may take the form of a
pooled estimate, a conﬁdence interval, quoting a p-value
only, or performing a meta-regression. Studies entailing
only qualitative evidence synthesis, although having an
essential role to play in the assessment of adverse events,
were not included in this review, which is exclusively
aimed at statistical synthesis methods. Meta-analyses of
unintended or adverse reactions associated with non-
interventional activities, for example recreational drug
use, were excluded.
Included reviews were evaluated on multiple aspects.
These included type of intervention, number of primary
studies incorporated, number of individual meta-analyses
performed and source of funding (when determin-
ing sponsorship, any form of commercial funding was
counted as such, even if other sources of funding were also
present; similarly, government sponsorship took prece-
dence over academic). The statistical aspects included
general meta-analysis methods and how speciﬁc chal-
lenges were addressed. These included (i) dealing with
sparse data (a count of zero events in one arm of study or
zero events across the whole study); (ii) statistical hetero-
geneity; (iii) dissemination biases (primarily publication
bias); (iv) variable quality of primary studies; and (v) use
of individual patient data (IPD).
Results
Description of included reviews
In total, 166 reviews including a meta-analysis fulﬁlled
all criteria and were included in this systematic review
[10-175]. Of these, 14 were Cochrane reviews, the others
were published in a wide variety of medical journals or
were reviews published by health agencies. Table 1 shows
a breakdown of number of included reviews by publica-
tion year and type.
Table 1 Number of included reviews by year of publication
Year of No. included Published Cochrane Other publication
publication reviews (%)1 in journal review type
1994 4 (2.4) 4 0 0
1995 8 (4.8) 8 0 0
1996 9 (5.4) 9 0 0
1997 15 (9.0) 15 0 0
1998 16 (9.6) 16 0 0
1999 19 (11.4) 18 1 0
2000 11 (6.6) 11 0 0
2001 22 (13.3) 22 0 0
2002 21 (12.7) 17 2 2
2003 22 (13.3) 20 2 0
2004 13 (7.8) 10 3 0
2005 4 (2.4) 0 4 0
2006 2 (1.2) 0 2 0
1Out of 166 included reviews.
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The interventions being evaluated for adverse events
were similarly diverse; by far the largest category was drug
interventions (69.9%, 116/166). The next largest category
was surgical interventions (8.4%, 14/166). Other types
of intervention, such as forms of anaesthesia, devices,
and diagnostic procedures, each accounted for fewer
than 5% of the included reviews. Multiple interventions
(often multiple therapies for cancer being assessed simul-
taneously) were considered by 5.4% (9/166) of included
reviews.
With regard to sponsorship, the largest number of
included reviews were academically sponsored (45.8%;
76/166). Commercial sponsorship accounted for 16.3%
(27/166), while 30.1% (50/166) were sponsored by some
form of government body. Other sponsorship sources pro-
vided funding for 7.2% (12/166), while funding source was
not stated for one included review.
Of the 166 included reviews, all except one included
some overall combined estimate. The one included review
that did not report a combined estimate included a meta-
regression for dose–response with no overall pooled esti-
mate of eﬀect size.
The number of meta-analyses performed in each
included review was also very variable. In many cases
a large number of meta-analyses were performed, with
44.6% (74/166) of studies having more than 10 meta-
analyses. By comparison, 19.3% (32/166) of studies had
6 −10 meta-analyses, 29.5% (49/166) had 2–5 meta-
analyses, 6.0% (10/166) had only one meta-analysis while
0.60% (1/166) had none (meta-regression only).
The number of primary cohorts (contributing a data
observation to themeta-analysis) is shown in Table 2. This
Table 2 Maximum andminimum numbers of contributing
estimates for meta-analyses in the same included review
Maximum no. Minimum no. No. included
data observations1 data observations reviews (%)2
2−5 2−5 17 (10.4)
6−10 2−5 34 (20.7)
6−10 6−10 6 (3.7)
11−20 2−5 50 (30.5)
11−20 6−10 5 (3.0)
11−20 11−20 4 (2.4)
>20 2−5 29 (17.7)
>20 6−10 12 (7.3)
>20 11−20 3 (1.8)
>20 >20 4 (2.4)
1A single primary study may contribute more than one data observation, hence
number of data observations may not be the same as number of primary studies.
2Out of 164 included reviews with at least one pooled estimate and number of
data observations stated.
table indicates that many included reviews performed
multiple meta-analyses with varying numbers of data
observations derived from primary studies, possibly
reﬂecting multiple outcomes or subgroup analyses.
Statistical methodology aspects
Table 3 sets out the number of included reviews that cover
heterogeneity, quality and dissemination bias, by year of
publication, to examine any changes over time.
Outcomemeasures
Table 4 shows the proportions of included reviews using
diﬀerent eﬀect measures. This is important because the
choice of outcome measure may in itself inﬂuence the
meta-analysis method and results.
In Table 4 the option ‘More than one’ was only selected
in the eventuality that there was no obvious primary out-
come metric, but instead at least two outcome metrics
that appeared to receive approximately equal importance
in the meta-analyses. Otherwise, the primary outcome
measure was recorded even if there were other outcome
metrics used in secondary analyses such as sensitivity
analyses.
Many of the outcomes being reported in the primary
studies were binary, thus lending themselves to analysis
by odds ratio or relative risk, as seen in Table 4. A dif-
ference scale (for example risk diﬀerence), as opposed to
a ratio scale, was chosen only infrequently. Only 9.6%
of studies presented more than one outcome measure.
This indicated that either more than one clinical outcome
was being investigated, requiring a diﬀerent outcomemet-
ric, or that the authors had presented analyses for the
same clinical outcome on equal terms for diﬀerent out-
comemetrics, possibly intended as a comparison between
the two.
Meta-analysis methodology
Another major area of interest was the methodology
used for the meta-analysis itself. Table 5 sets out the
meta-analysis method used to combine studies along with
numbers and percentages.
As seen in Table 5, ﬁxed and random eﬀect(s) models
were used with roughly equal frequency. The term ‘stan-
dard ﬁxed eﬀect’ was used when the authors chose an
accepted ﬁxed eﬀect model, such as the Mantel–Haenszel
model [176], the inverse variance model or the Peto
model [177]. Also, if the authors used any referenced ﬁxed
eﬀect model this was recorded as ‘standard ﬁxed eﬀect’. In
several cases the authors had used a method of combining
data that would be considered as a ‘ﬁxed eﬀect’ model, but
appeared to have either used a mean or weighted mean,
or a logistic regression method, or had devised their own
method for combining data, for example based on sam-
ple size of the studies. Such methods were considered
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Table 3 Percentages of included reviews by year including assessment of heterogeneity, quality and dissemination bias
Total no. included Heterogeneity Quality Dissemination bias
Year reviews (no. (%)) (no. (%)) (no. (%))
1994 4 2 (50) 1 (25) 1 (25)
1995 8 7 (88) 1 (13) 4 (50)
1996 9 8 (89) 1 (11) 6 (67)
1997 15 12 (80) 8 (53) 5 (33)
1998 16 14 (88) 3 (19) 10 (63)
1999 19 18 (95) 8 (42) 12 (63)
2000 11 9 (82) 4 (36) 4 (36)
2001 22 19 (86) 8 (36) 15 (68)
2002 21 16 (76) 13 (62) 8 (38)
2003 22 16 (73) 10 (45) 15 (68)
2004 13 11 (85) 7 (54) 5 (38)
2005 4 4 (100) 4 (100) 3 (75)
2006 2 2 (100) 2 (100) 1 (50)
non-standard and were recorded as ‘other ﬁxed eﬀect’.
Interestingly, all the random eﬀects models were
referenced standard models (referred to as standard ran-
dom eﬀects in Table 5, such as the DerSimonian & Laird
model [178]).
A record of ‘Multiple analysis methods’ was only
selected when there was more than one method used on
an equal basis. If there was an obvious primary method
Table 4 Measure of eﬀect
Measure of No. included Percent included
eﬀect reviews reviews1
Comparative measures (between interventions)
Odds ratio 55 33.1
Relative risk 51 30.7
Risk diﬀerence 8 4.8
Mean diﬀerence 6 3.6
Standardised mean diﬀerence 7 4.2
Percent diﬀerence 2 1.2
Non-comparative measures
Correlation 2 1.2
Probability (or percent) 13 7.8
Mean diﬀerence 2 1.2
Percent diﬀerence 3 1.8
Multiple measures
More than one 16 9.6
Other measures
Other 1 0.6
1Out of 166 included reviews.
with additional supplementary methods the primary me-
thod was chosen.
The one meta-analysis reference referred to as ‘Other’
used a novel approach developed by the authors of ‘sum-
mary ranking’ involving assigning a score to the rank order
of toxicity in individual primary studies, and then combin-
ing the scores to provide an overall rank order for toxicity.
One study included a meta-regression as the only quanti-
tative analysis, whilst another study performed a test for
heterogeneity but did not produce any pooled estimates.
In only three cases was there insuﬃcient detail regarding
the methodology to allow the type of analysis to be deter-
mined. In ﬁve of the reviewed studies the meta-analysis
method was not stated.
Table 5 Meta-analysis methods
Meta-analysis No. included Percent included
method reviews reviews1
Standard ﬁxed eﬀect2 54 32.5
Other ﬁxed eﬀect2 9 5.4
Standard random eﬀects2 50 30.1
Marginal analysis 3 1.8
Bayesian methods 6 3.6
Multiple analysis methods 33 19.9
Other 1 0.6
Not stated 5 3.0
Meta-regression only 1 0.6
Heterogeneity test only 1 0.6
Unclear 3 1.8
1Out of 166 included reviews.
2See text for deﬁnition.
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 5 of 14
http://www.biomedcentral.com/1471-2288/12/64
A Bayesian approach was used by six included reviews,
but in some cases the Bayesian model used in the
meta-analysis was not fully described. Semi-Bayesian
methods, incorporating a Bayesian use of a prior distri-
bution on the rate of the adverse event alongside stan-
dard frequentist methods, were also used in one included
review. This meta-analysis also experimented with the
use of diﬀerent prior distributions for the parameters.
However, none of these studies presented graphical repre-
sentations of the probability densities for the parameters.
Not taking into account the speciﬁcmethod of themeta-
analysis, 74/166 (44.6%) used a ﬁxed eﬀect model. This
included one review that stated that a random eﬀects
model was used, but in the absence of heterogeneity the
presented results were ﬁxed eﬀect. (The novel method
using rank summaries was also a ﬁxed eﬀect approach.)
Three included reviews where the methodology was not
described in suﬃcient detail to be classed as a standard or
other ﬁxed eﬀect model, were, however, able to be classed
as ﬁxed eﬀect in their approach.
A random eﬀects model was used by 53/166 (31.9%)
included reviews, including four of the reviews that used
Bayesian methods. Hence, it is apparent that ﬁxed and
random eﬀect(s) models were used with roughly equal
frequency.
Both ﬁxed and random eﬀect(s) models were used in
28/166 (16.9%) included reviews, including one that used
Bayesian methods. In the other cases it was not applicable
(5/166; 3.0%), or not stated (5/166; 3.0%). It was unclear
whether ﬁxed or random eﬀect(s) had been used in one
included review only.
The reasons why the authors chose a particular model
were recorded in 69/166 (41.6%) included reviews.
Reasons based upon heterogeneity (or between-study
variation) were the most commonly cited (46/69; 66.7%).
Increased conservatism (of a random eﬀects model) was
also frequently mentioned; 7/69 (10.1%) reviews alluded
to this.
Other reasons cited in support for a particular meta-
analysis method included diﬀerences in primary study
types, and so that larger studies would contribute more
to the meta-analysis. Arriving at similar results from both
ﬁxed and random eﬀect(s) models was also used to justify
the chosen approach. Only one included review oﬀered
multiple explanations, while nine oﬀered an explanation
not mentioned above.
Type of primary study and approaches to inclusion
The types of primary study encountered by included
reviews are set out in Table 6. The most frequent study
type was some form of trial, the sole study type for
46.4% (77/166) of included reviews. Trials were clearly
deﬁned as being randomised and/or controlled in some
included reviews. The 26 reviews (26/166, 15.7%) that
Table 6 Primary study types incorporated within included
reviews
Study types No. included reviews % included reviews1
Randomised trials 70 42.2
Other trials2 7 4.2
Observational studies 56 33.7
Mixed (trials and
observational studies) 26 15.7
Not stated 7 4.2
1Out of 166 included reviews.
2May include randomised trials but not speciﬁcally stated as such.
included both trials and observational studies demon-
strated a wide variety of approaches taken to this situation,
often reﬂecting the number of each diﬀerent type of study.
Some included reviews made no attempt to diﬀerentiate
by study design. In some included reviews there was only
one trial, all other studies were observational, and in one
of these reviews, the trial was excluded, although its inclu-
sion did not alter the results. In another instance with only
one trial, it was excluded from all meta-analyses, only the
observational studies (of diﬀerent designs) being included.
In one included review the sole trial was excluded due to
no events being observed in one group of the trial; simi-
larly, in another review with only one trial, this study was
excluded due to the small number of outcome events.
The most common approach to mixed study types was
to perform a sensitivity analysis by analysing all pri-
mary studies together and then dividing the studies by
some element of study design. For example, one included
review combined all studies together and then case–
control studies were analysed separately, and cohort stud-
ies were combined with trials. Some variation on this
theme was followed by several other included reviews.
Another approach was to avoid combination of estimates
across study designs altogether, by combining results from
studies with similar designs.
Graphical representations of data
Graphical representations of data were used in the major-
ity of included reviews. Forest plots were the only graph
used in 53.0% (88/166) of reviews, while meta-regression
plots were the only plot in 1.8% (3/166). Both forest plots
and meta-regression plots appeared in 1.8% (3/166) of
included reviews. Other plots were used in 18.1% (30/166)
of included reviews, usually a plot of the individual stud-
ies but lacking a pooled estimate. Only 25.3% (42/166) of
included reviews produced no graphical representations
of their results.
Publication Bias
Publication bias was considered in 89/166 (53.6%) of
included reviews. This issue may not have been speciﬁ-
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 6 of 14
http://www.biomedcentral.com/1471-2288/12/64
cally described in terms of publication bias. For example,
some included reviews performed searches for unpub-
lished primary studies, indicating that publication bias
was within the awareness of the authors when performing
a meta-analysis even if it was not taken any further than
searching for such primary studies.
Publication bias was discussed but not formally eval-
uated in 44/166 (26.5%) included reviews. A quantita-
tive analysis was performed by 31/166 (18.7%) included
reviews. A sensitivity analysis by publication status was
the preferred method of investigating publication bias for
one review.
Of 31 included reviews with some form of quantitative
analysis, 12 (38.7%) used a test with a p-value. The other
19/31 (61.3%) used an alternative method not resulting
in a p-value. The most commonly used tests were Egger’s
test [179] and Begg’s test [180]. Kendall’s tau test was
mentioned by three included reviews.
The trim and ﬁll method [181] was used to adjust for
publication or selection bias in two included reviews.
These were the only reviews that attempted to adjust for
these types of bias. Graphical methods (funnel plots) were
used to investigate for publication bias (or selection bias)
in 29/166 reviews (17.5%).
The vast majority of included reviews used only pub-
lished primary studies (129/166; 77.7%). Published pri-
mary studies with unpublished data (obtained through
contact with the authors), were used in 20/166 (12.0%)
included reviews. Both published and unpublished pri-
mary studies were used in 14/166 (8.4%) reviews. In the
other reviews the study source(s) was either unclear or not
stated. In several reviews where published primary stud-
ies only were included, it was made clear that unpublished
data had been sought.
Heterogeneity
Heterogeneity was considered in somemanner by 138/166
included reviews (83.1%), whether by a quantitative or
qualitative assessment, or by a subgroup analysis or meta-
regression. Meta-regression was included in nine reviews
that had no other assessment of heterogeneity, whilst one
review discussed issues regarding combination of primary
studies with diﬀerent criteria, but did not do a formal
qualitative or quantitative analysis of heterogeneity. Of
the remaining 128 included reviews, a quantitative assess-
ment was performed in 124 (124/166; 74.7%). A qualita-
tive assessment of heterogeneity (for example, inspection
of forest plots or noting heterogeneous results) was made
in 10/166 (6.0%) included reviews. Six included reviews
incorporated both quantitative and qualitative aspects of
heterogeneity assessment (6/166; 3.6%).
Considering quantitative analysis methods, 121/166
(72.9%) included reviews employed some form of statis-
tical test for heterogeneity, although with variation in the
chosen critical p-value for signiﬁcance. The chosen sig-
niﬁcance value was 0.05 for 28 reviews (23.1% of the 121
studies that performed a test), while 23/121 chose a more
liberal p-value of 0.1 (19.0%). Only one included review
chose 0.2 as the cut-oﬀ p-value. In many reviews the
actual p-value was quoted without reference to a partic-
ular threshold (51/121 reviews (42.1%) did this). In the
other reviews no p-value or signiﬁcance level was stated.
An estimate for heterogeneity was presented by 16/121
included reviews with a quantitative analysis (13.2%).
The most frequently-used estimate measure was the I2
statistic [182,183], which was used in 13 reviews. Alter-
native estimate measures included the between-studies
variance. One review used another estimate measure, the
R(I) statistic [184]. Only one included review used multi-
ple estimate measures; the estimates used included I2 and
the Q statistic [185].
Two ways to investigate the causes of heterogeneity are
subgroup analysis andmeta-regression. Subgroup analysis
was performed in 27/128 (21.1%) reviews that included an
analysis of heterogeneity, and in two reviews that did not
formally assess heterogeneity. Meta-regression was used
in 27 included reviews in total (27/166; 16.3%). In nine
of these reviews, no formal assessment of heterogeneity
had been performed. The covariates used in the meta-
regression analyses were often very speciﬁc to the nature
of the intervention or outcome being considered. A quali-
tative investigation of sources of heterogeneity was carried
out in 17/138 reviews that considered heterogeneity in
some way (12.3%).
Individual patient data
Very little use was made of IPD in the reviewed meta-
analyses. Only two included reviews of the total 166
(1.2%) included IPD. Of these two, all primary studies
included had IPD available (so there was no requirement
to combine IPD and summary data). Both reviews used
a one-stage method for the meta-analysis. In one review
the meta-analysis was stratiﬁed by trial and other factors
including centre within study for multicentre studies and
age divisions. In the other review it was not stated whether
the meta-analysis was stratiﬁed or not.
Sparse data
The issue of sparse data, whereby statistical methods were
required to allow the inclusion of primary studies where
the outcome was a count of zero, or a percent of zero,
occurred in 65/166 included reviews (39.2%), one of which
was a meta-analysis of single-arm studies only. Speciﬁc
statistical methods may be required to allow incorpo-
ration of such a primary study into an overall pooled
estimate or for calculation of conﬁdence intervals. For 62
of the 65 reviews in which sparse data occurred, the out-
come was on a comparative scale (an odds ratio, relative
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risk, or risk diﬀerence); this methodological area is the
focus of this review. The primary issues are (i) outcome
measures used by meta-analyses with zero events; (ii)
use of continuity corrections; (iii) methods for inclusion
of primary studies with zero events that do not involve
continuity corrections; and (iv) incorporation of primary
studies with zero events in both arms.
Of the 64 included reviews that considered the issue of
sparse data in two-arm studies, 41 (64.1%) had datasets
involving double-zero (zero events in both arms) primary
studies. In the remaining 23 reviews, only single-zero
(zero events in only one arm of a two-arm study) pri-
mary studies were present, or it was either unclear or
not directly stated whether any double-zero studies were
included within the dataset.
Of these 64 reviews, 30 (46.9%) presented their outcome
as an odds ratio, 24 (37.5%) as a relative risk, and two as
a risk diﬀerence. In six included reviews, there was more
than one outcome with roughly equal importance in the
meta-analyses. In two reviews, the outcome, where sparse
data were incorporated, was an incidence rate.
Continuity corrections were used to circumvent prob-
lems with zero counts (in one or both arms of a study) that
result in diﬃculties with estimating ratio-based outcome
measures such as the odds ratio. Continuity corrections
are also required to calculate the variance (and hence con-
ﬁdence intervals) for a risk diﬀerence. However, it was
very diﬃcult to determine an accurate picture of how
continuity corrections were used.
Some included reviews clearly stated that continuity
corrections had been used (15/64, 23.4%). In 17/64 (26.6%)
included reviews, continuity corrections were not used.
In 32 cases it was not clearly stated whether continuity
corrections had been used or not.
The most popular primary continuity correction was
0.5, used in 14 of the 15 included reviews that stated their
continuity correction. Only one meta-analysis reference
used an alternative continuity correction with 0.25 being
the chosen value. Only one review performed a sensitivity
analysis across diﬀerent continuity corrections, using 0.5,
0.1 and 0.01, and reported that the continuity correction
did not alter the results. Three included reviews provided
a reason for their choice of continuity correction, and the
only reason cited was to minimise bias.
Several methods for incorporating single- and double-
zero studies into a meta-analysis that do not involve
continuity corrections were encountered in the included
reviews. The most frequently used was the Peto
method, employed by 12 studies. The use of a diﬀerence
metric rather than a ratio as the outcome measure
was used to circumvent problems with zeroes in seven
reviews, although calculation of conﬁdence intervals with
such methods would be problematic. Seven included
reviews resorted to the use of marginal analysis. Bayesian
methods were used to tackle sparsity of events in only two
included reviews.
Double-zero studies were included in analyses in 17 of
the 41 reviews where double-zero primary studies were
clearly present within the dataset. In two further reviews,
double-zero studies were included in a sensitivity analysis.
Double-zero studies were clearly excluded from analyses
in 18 reviews where they were present in the set of pri-
mary studies. Such an exclusion was either a deliberate
decision by the authors, shown by excluding the primary
study in forest plots of the meta-analysis, or was done by
default, the primary study being shown on a forest plot,
but being given a weighting of zero. The four remaining
included reviews were unclear as to whether or not these
double-zero primary studies were included.
Of the 19 included reviews where double-zero primary
studies were included in some way, seven made explicit
use of continuity corrections. In other included reviews
it was not clearly stated whether continuity corrections
had been used. Other options, such as using a marginal
analysis, were employed in some reviews, whilst in other
reviews the methodologies used were unclear.
Discussion
This paper has reviewed an extensive sample of pub-
lished meta-analyses where the primary outcome was an
adverse or unintended event. Reviews published in lan-
guages other than English were excluded, hence there is
a risk that methodologies used in reviews published in
other languages may diﬀer from those discussed here.
There was considerable variation in the methodology
employed across the sample, including designs of the pri-
mary studies incorporated in the meta-analyses, use of
ﬁxed or random eﬀect(s) measures, how to deal with
zero events in study arms, and how to assess study qual-
ity and publication bias. In many cases, the statistical
aspects were not clearly reported, with insuﬃcient detail
to discern the methods used. Often, little justiﬁcation
was given for the approaches to meta-analysis used. This
is perhaps, in part, due to the lack of speciﬁc guide-
lines available for meta-analysis of sparse/adverse events.
Not only would such guidelines improve the standard of
reporting of adverse event meta-analyses, they could also
circumvent disagreements in the literature due to the use
of alternative methods producing diﬀerent conclusions,
as was the case for the recent high-proﬁle concerns of
elevated cardiovascular risk in those taking rosiglitazone
[186-190].
Based on this review, one of the major areas of confu-
sion appears to be with regard to the use of continuity
corrections for dealing with sparse data for comparative
outcomes. Indeed the term continuity correction is pos-
sibly misleading, as these are in eﬀect nothing more than
arbitrary factors added to a cell count of zero. Where
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a study has zero events in both groups, we believe it
contains no information regarding the magnitude of the
odds ratio or relative risk, but adding a continuity correc-
tion to both sides (incorrectly) keeps it in the analysis for
methods which require it. Although not required for the
risk diﬀerence scale, and such a study does contain infor-
mation, a correction factor is required for the estimation
of associated variance which causes further confusion.
This latter point also raises the unanswered question of
whether the presence of double-zero studies should inﬂu-
ence the outcome metric. Bayesian methods present an
alternative way to deal with datasets including sparse data,
and Bayesian analyses are now easily implemented using
appropriate software. However, Bayesian methods were
used infrequently within the included reviews; with the
development of guidelines to support Bayesian analyses, it
may be that such methods would become more popular.
Many reviews in this sample included observational
studies, in some cases this was the only type of pri-
mary study included, whilst in other reviews both obser-
vational studies and trials were included. Observational
studies may oﬀer advantages over trials, such as a longer
period of follow-up. Inclusion of observational studies
also increases the number of studies and individuals
within ameta-analysis where both trials and observational
studies are available, thus increasing power. However, this
advantage may be counterbalanced by concerns regarding
bias in observational studies. The reviews included here
showed a variety of approaches to mixed study design; this
is an area where guidelines would assist in combining all
available data whilst addressing issues of diﬀerent study
design.
As mentioned in the introduction, a previous systematic
review of reviews and meta-analyses of primary studies of
adverse eﬀects of a drug intervention has been conducted
[4], including a total of 43 references, all published in 2006.
Of these, 15% assessed quality of primary studies, com-
pared to 42.2% of references in our review, and only 24
performed a meta-analysis. As seen in our review, there
was some poor reporting of the methods used for pool-
ing data, but 83% did report the method used for pooling
data and exploring heterogeneity. With regard to funding
source, 23% (of the 43 reviews) had pharmaceutical fund-
ing, compared to the 16.3% of references in our review that
had commercial funding. Hence, there is potentially some
suggestion of systematic diﬀerences between reviews con-
cerning only drugs and those including other interven-
tions, and between reviews that contain a meta-analysis
and those that do not (although such observations could
be confounded by the wider time range we considered).
Development of guidelines
Within the ﬁeld of meta-analysis for adverse events, the
concept of deﬁnitive guidelines is possibly too prescrip-
tive; the diverse nature of medical interventions, the
potential adverse outcomes and the ways they may be
measured, and the formats in which data may be available
preclude the use of standardised methods. However, gen-
eral guidelines for approaching speciﬁc methodological
issues (applying to other outcomes beyond adverse events)
may be more feasible and useful. We hope this review sets
the context in which future research and guidelines into
the conduct of adverse event meta-analyses can be placed.
There is perhaps a need for more research before
informed guidelines could be drafted. Many of the unique
issues relating to adverse event meta-analyses are due to
the typically sparse event data available for such analyses.
Such sparse data presents unique challenges, as high-
lighted by this review. As well as speciﬁc challenges, such
as dealing with zero events in arms of studies, there are
also potential concerns relating to the use of broadly
accepted meta-analysis methods in a sparse data context
due to the potentially very low power such methods may
have. For example, simulation has shown that tests for
heterogeneity have very low power in sparse data situa-
tions [191,192]. Similar issues are likely to exist for the
use of meta-regression, tests for publication bias [193] and
other methodologies. Rather than trying to use cutting-
edge advanced meta-analysis methodology, in a sparse
data context, it may often be wiser to restrict focus to
simpler methods (e.g. ﬁxed eﬀect models) and be real-
istic about the potentially limited conclusions that can
be drawn from the data. Since the primary aim of many
adverse eﬀect meta-analyses is to establish the existence
of an elevated risk of an event due to a particular inter-
vention, use of simple methods is, perhaps, consistent
with this aim. Information on the performance of diﬀer-
ent meta-analytic estimators for sparse data and the use
and avoidance of correction factors has been considered
at length elsewhere [191,192] and this is one domain in
which knowledge on which methods to use and which to
avoid is available.
Hierarchical models to address issues related to combi-
nation of diﬀerent study types have been developed [194],
and more recent developments on the use of methods to
adjust studies in meta-analysis to account for bias appear
to be promising [195,196]. However, further exploration
into the use of such methods in an adverse events context
is warranted.
Development of Bayesian methods is clearly an area
where further research would be both timely and ben-
eﬁcial, especially in the light of many of the diﬃcul-
ties surrounding meta-analysis of adverse events data,
which Bayesian methods may be able to address, such as
inclusion of primary studies with sparse events without
the need for continuity corrections using Markov Chain
Monte Carlo (MCMC) methods [197-200]. However, dif-
ﬁculties exist in ensuring that all prior distributions are
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plausibly vague, when not based on external information
– a challenge given how little data is sometimes available
[201,202].
Speciﬁcally to adverse events, an area where further
research would be valuable is the consideration of drug
class eﬀects, allowing information on multiple drugs of
the same class to be combined while acknowledging the
potential diﬀerences in eﬀects across drugs. This would
be an area where hierarchical (and potentially Bayesian)
models would be particularly useful [203]. Another clini-
cal aspect related to adverse events issues is that there may
be several indications for a certain intervention; patients
with diﬀerent conditions may be at varying risk of adverse
events, despite receiving the same intervention. Whilst it
is desirable to combine all available data to increase power,
any meta-analysis should be able to adjust for the diﬀer-
ences in indication for the intervention; as this scenario is
similar to combination of data regarding individual drugs
of the same class, hierarchical modelling may be a means
to achieve this.
Conclusion
Conducting meta-analyses where the outcome is an unin-
tended or adverse event presents a range of potential
diﬃculties, and requires careful consideration of the sta-
tistical issues, as well as an awareness of the clinical
context. This review has demonstrated that a diversity of
approaches have been employed when conducting such
meta-analyses. Hence, standardised guidelines may be
beneﬁcial in this area, even if, due to the range of clini-
cal situations and availability and format of data, they are
necessarily of a general nature. This is especially true since
a meta-analysis may present the only feasible method
to estimate potential risks, due to the often infrequent
occurrence of adverse events within an individual trial or
observational study.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FCW selected and reviewed the included references, with guidance from KRA
and AJS. SG developed the online search strategies and performed all
literature searches (online and by hand). FCW drafted the paper, which was
revised by all co-authors. All authors read and approved the ﬁnal version of the
manuscript for publication.
Acknowledgements
FCW performed this study whilst being supported by a studentship from the
Department of Health Sciences, University of Leicester. KRA is partially
supported by a National Institute for Health Research (NIHR) Senior
Investigator Award (NI-SI-0508-10061). There were no sources of external
funding for this study. The authors would like to thank the reviewers for their
useful and supportive comments.
Author details
1Peninsula College of Medicine and Dentistry, St Luke’s Campus, University of
Exeter, Exeter, EX1 2LU, UK. 2Department of Health Sciences, Adrian Building,
University of Leicester, University Road, Leicester, LE1 7RH, UK. 3Centre for
Reviews and Dissemination (CRD), University of York, York, YO10 5DD, UK.
Received: 14 June 2011 Accepted: 16 April 2012
Published: 3 May 2012
References
1. Loke YK, Price D, Herxheimer A, Cochrane Adverse Eﬀects Methods
Group: Systematic reviews of adverse eﬀects: framework for a
structured approach . BMCMedical ResearchMethodology 2007, 7:32.
2. Loke YK, Price D, Herxheimer A: Adverse eﬀects. In Cochrane Handbook
for Systematic Reviews of Interventions. Edited by Higgins JPT, Green S.
Chichester, UK: John Wiley and Sons; 2008:433–449.
3. Sutton A, Cooper N, Lambert P, Jones D, Abrams K, Sweeting M:
Meta-analysis of rare and adverse event data. Expert Review of
Pharmacoeconomics and Outcomes Research 2002, 2(4):367–379.
4. Cornelius VR, Perrio MJ, Shakir SAW, Smith LA: Systematic reviews of
adverse eﬀects of drug interventions: a survey of their conduct
and reporting quality. Pharmacoepidemiology and Drug Safety 2009,
18(12):1223–1231.
5. Derry S, Loke YK, Aronson JK: Incomplete evidence: the inadequacy
of databases in tracing published adverse drug reactions in clinical
trials. BMCMedical Research Methodology 2001, 1:7.
6. Golder S, McIntosh HM, Duﬀy S, Glanville J: Developing eﬃcient
search strategies to identify reports of adverse eﬀects in MEDLINE
and EMBASE. Health Information and Libraries Journal 2006, 23(1):3–12.
7. Golder S, McIntosh HM, Loke Y: Identifying systematic reviews of the
adverse eﬀects of health care interventions. BMCMedical Research
Methodology 2006, 6:22.
8. Golder S, Loke Y, McIntosh HM: Room for improvement? A survey of
the methods used in systematic reviews of adverse eﬀects. BMC
Medical ResearchMethodology 2006, 6:3.
9. Golder S, Loke Y, McIntosh HM: Poor reporting and inadequate
searches were apparent in systematic reviews of adverse eﬀects.
Journal of Clinical Epidemiology 2008, 61(5):440–448.
10. Alﬁrevic Z, Sundberg K, Brigham S: Amniocentesis and chorionic villus
sampling for prenatal diagnosis . Cochrane Database of Systematic
Reviews 2003 doi:10.1002/14651858.CD003252. Issue 3(Art. No.:
CD003252).
11. Allen DB, Mullen M, Mullen B: Ameta-analysis of the eﬀect of oral
and inhaled corticosteroids on growth. Journal of Allergy and Clinical
Immunology 1994, 93(6):967–976.
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC,
Weiden PJ: Antipsychotic-induced weight gain: a comprehensive
research synthesis. American Journal of Psychiatry 1999,
156(11):1686–1696.
13. Anderson JW, Kendall CWC, Jenkins DJA: Importance of weight
management in Type 2 diabetes: review with meta-analysis of
clinical studies. Journal of the American College of Nutrition 2003,
22(5):331–333.
14. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE:
Neuropsychological eﬀects of treatments for adults with cancer: a
meta-analysis and review of the literature. Journal of the International
Neuropsychological Society 2003, 9(7):967–982.
15. Ashcroft DM, Chapman SR, Clark WK, Millson DS: Upper
gastroduodenal ulceration in arthritis patients treated with
celecoxib. Annals of Pharmacotherapy 2001, 35(7–8):829–834.
16. Ashraf E, Cooper S, Kellstein D, Jayawardena S: Safety proﬁle of
nonprescription ibuprofen in the elderly osteoarthritis patient: a
meta-analysis. Inﬂammopharmacology 2001, 9(1–2):35–41.
17. Banks E: Hormone replacement therapy and the sensitivity and
speciﬁcity of breast cancer screening: a review. Journal of Medical
Screening 2001, 8(1):29–35.
18. Barbui C, Saraceno B: Low-dose neuroleptic therapy and
extrapyramidal side eﬀects in schizophrenia: an eﬀect size
analysis. European Psychiatry 1996, 11(8):412–415.
19. Barone JE, Tucker JB, Rassias D, Corvo PR: Routine perioperative
pulmonary artery catheterization has no eﬀect on rate of
complications in vascular surgery: a meta-analysis. American
Surgeon 2001, 67(7):674–679.
20. Ben-David S, Einarson T, Ben-David Y, Nulman I, Pastuszak A, Koren G:
The safety of nitrofurantoin during the ﬁrst trimester of
pregnancy: meta-analysis. Fundamental and Clinical Pharmacology
1995, 9(5):503–507.
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 10 of 14
http://www.biomedcentral.com/1471-2288/12/64
21. Bender BG, Berning S, Dudden R, Milgrom H, Tran ZV: Sedation and
performance impairment of diphenhydramine and
second-generation antihistamines: a meta-analysis. Journal of
Allergy and Clinical Immunology 2003, 111(4):770–776.
22. Berglundh T, Persson L, Klinge B: A systematic review of the incidence
of biological and technical complications in implant dentistry
reported in prospective longitudinal studies of at least 5 years.
Journal of Clinical Periodontology 2002, 29(Supplement 3):197–212.
23. Bernal-Delgado E, Latour-Perez J, Pradas-Arnal F, Gomez-Lopez LI: The
association between vasectomy and prostate cancer: a systematic
review of the literature. Fertility and Sterility 1998, 70(2):191–200.
24. Brown JS, Sawaya G, Thom DH, Grady D: Hysterectomy and urinary
incontinence: a systematic review. Lancet 2000, 356(9229):535–539.
25. Brown S, Small R, Faber B, Krastev A, Davis P: Early postnatal discharge
from hospital for healthy mothers and term infants. Cochrane
Database of Systematic Reviews 2002 doi:10.1002/14651858.CD002958.
Issue 3(Art. No.: CD002958).
26. Brumback BA, Holmes LB, Ryan LM: Adverse eﬀects of chorionic villus
sampling: a meta-analysis. Statistics in Medicine 1999,
18(16):2163–2175.
27. Cannegieter SC, Rosendaal FR, Briet E: Thromboembolic and bleeding
complications in patients with mechanical heart valve prostheses.
Circulation 1994, 89(2):635–641.
28. Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ: Changes in
bone density after exposure to oral anticoagulants: a
meta-analysis. Osteoporosis International 1999, 9(5):441–448.
29. Cardwell ME, Siviter G, Smith AF: Non-steroidal anti-inﬂammatory
drugs and perioperative bleeding in paediatric tonsillectomy.
Cochrane Database of Systematic Reviews 2005
doi:10.1002/14651858.CD003591.pub2. Issue 2(Art. No.: CD003591).
30. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvarez
Requejo A, Rodriguez Pinilla E: Is metronidazole teratogenic: a
meta-analysis. British Journal of Clinical Pharmacology 1997,
44(2):179–182.
31. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, Ginsberg JS:
Risk of stroke in women exposed to low-dose oral contraceptives:
a critical evaluation of the evidence. Archives of Internal Medicine
2004, 164(7):741–747.
32. Chang CH, Chen KY, Lai MY, Chan KA:Meta-analysis: ribavirin-induced
haemolytic anaemia in patients with chronic hepatitis C. Alimentary
Pharmacology and Therapeutics 2002, 16(9):1623–1632.
33. Chapron C, Fauconnier A, Goﬃnet F, Breart G, Dubuisson JB:
Laparoscopic surgery is not inherently dangerous for patients
presenting with benign gynaecologic pathology: results of a
meta-analysis. Human Reproduction 2002, 17(5):1334–1342.
34. Choi PT, Galinski SE, Takeuchi L, Lucas S, Tamayo C, Jadad AR: PDPH is a
common complication of neuraxial blockade in parturients: a
meta-analysis of obstetrical studies. Canadian Journal of Anaesthesia
2003, 50(5):460–469.
35. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J: Hormone
replacement therapy after breast cancer: a systematic review and
quantitative assessment of risk. Journal of Clinical Oncology 2001,
19(8):2357–2363.
36. Collaborative Group on Hormonal Factors in Breast Cancer: Breast
cancer and hormonal contraceptives: collaborative reanalysis of
individual data on 53 297 women with breast cancer and 100 239
women without breast cancer from 54 epidemiological studies.
Lancet 1996, 347(9017):1713–1727.
37. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia
associated with second-generation antipsychotics: a systematic
review of 1-year studies. American Journal of Psychiatry 2004,
161(3):414–425.
38. Coughlin SS, Giustozzi A, Smith SJ, Lee NC: Ameta-analysis of
estrogen replacement therapy and risk of epithelial ovarian
cancer. Journal of Clinical Epidemiology 2000, 53(4):367–375.
39. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH: Acute
and chronic graft-versus-host disease after allogeneic
peripheral-blood stem-cell and bonemarrow transplantation: a
meta-analysis. Journal of Clinical Oncology 2001, 19(16):3685–3691.
40. Derry S, Loke YK: Risk of gastrointestinal haemorrhage with long
term use of aspirin: meta-analysis. BMJ 2000, 321(7270):1183–1187.
41. Dezfulian C, Lavelle J, Nallamothu BK, Kaufman SR, Saint S: Rates of
infection for single-lumen versus multilumen central venous
catheters: a meta-analysis. Critical Care Medicine 2003,
31(9):2385–2390.
42. DiMatteo MR, Morton SC, Lepper HS, Damush TM, Carney MF, Pearson
M, Kahn KL: Cesarean childbirth and psychosocial outcomes: a
meta-analysis. Health Psychology 1996, 15(4):303–314.
43. Dolovich LR, Addis A, Vaillancourt RJ, Power BJ, Koren G, Einarson TR:
Benzodiazepine use in pregnancy andmajor malformations of oral
cleft: meta-analysis of cohort and case-control studies. BMJ 1998,
317(7162):839–843.
44. Dong EW, Connelly JE, Borden SP, Yorzyk W, Passov DG, Kupelnick B, Luo
DH, Ross SD: A systematic review andmeta-analysis of the
incidence of cancer in randomized, controlled trials of verapamil.
Pharmacotherapy 1997, 17(6):1210–1219.
45. Doren M, Nilsson JA, Johnell O: Eﬀects of speciﬁc post-menopausal
hormone therapies on bonemineral density in post-menopausal
women: a meta-analysis. Human Reproduction 2003, 18(8):1737–1746.
46. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF:
A reevaluation of the risk for venous thromboembolism with the
use of oral contraceptives and hormone replacement therapy.
Archives of Internal Medicine 1997, 157(14):1522–1530.
47. Doyle LW, Davis PG: Postnatal corticosteroids in preterm infants:
systematic review of eﬀects onmortality andmotor function.
Journal of Paediatrics and Child Health 2000, 36(2):101–107.
48. Duﬀy G, Neal KR: Diﬀerences in post-operative infection rates
between patients receiving autologous and allogeneic blood
transfusion: a meta-analysis of published randomized and
nonrandomized studies. TransfusionMedicine 1996, 6(4):325–328.
49. Egger M, Davey Smith G, Stettler C, Diem P: Risk of adverse eﬀects of
intensiﬁed treatment in insulin-dependent diabetes mellitus: a
meta-analysis. Diabetic Medicine 1997, 14(11):919–928.
50. Eikelboom JW, Mehta SR, Pogue J, Yusuf S: Safety outcomes in
meta-analyses of phase 2 vs phase 3 randomized trials: intracranial
hemorrhage in trials of bolus thrombolytic therapy. JAMA 2001,
285(4):444–450.
51. Etminan M, Samii A, Takkouche B, Rochon PA: Increased risk of
somnolence with the new dopamine agonists in patients with
Parkinson’s disease: a meta-analysis of randomised controlled
trials. Drug Safety 2001, 24(11):863–868.
52. Etminan M, Gill S, Samii A: Comparison of the risk of adverse events
with pramipexole and ropinirole in patients with Parkinson’s
disease: a meta-analysis. Drug Safety 2003, 26(6):439–444.
53. Etminan M, Gill S, Samii A: Eﬀect of non-steroidal anti-inﬂammatory
drugs on risk of Alzheimer’s disease: systematic review and
meta-analysis of observational studies. BMJ 2003,
327(7407):128–131.
54. Fernandez E, La Vecchia, C, Balducci A, Chatenoud L, Franceschi S, Negri
E: Oral contraceptives and colorectal cancer risk: a meta-analysis.
British Journal of Cancer 2001, 84(5):722–727.
55. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in
mortality in patients with coronary heart disease. Circulation 1995,
92(5):1326–1331.
56. Gabriel Sa´nchez R, Carmona L, Roque M, Sa´nchez Gomez LM, Bonﬁll X:
Hormone replacement therapy for preventing cardiovascular
disease in post-menopausal women. Cochrane Database of Systematic
Reviews 2005 doi:10.1002/14651858.CD002229.pub2. Issue 2(Art. No.:
CD002229).
57. Garcia Rodriguez LA: Nonsteroidal antiinﬂammatory drugs, ulcers
and risk: a collaborative meta-analysis. Seminars in Arthritis and
Rheumatism 1997, 26(6 Supplement 1):16–20.
58. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ: Association
between aspirin and upper gastrointestinal complications:
systematic review of epidemiologic studies. British Journal of Clinical
Pharmacology 2001, 52(5):563–571.
59. Garg PP, Kerlikowske K, Subak L, Grady D: Hormone replacement
therapy and the risk of epithelial ovarian carcinoma: a
meta-analysis. Obstetrics and Gynecology 1998, 92(3):472–479.
60. Gillum LA, Mamidipudi SK, Claiborne Johnston S: Ischemic stroke risk
with oral contraceptives: a meta-analysis. JAMA 2000, 284(1):72–78.
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 11 of 14
http://www.biomedcentral.com/1471-2288/12/64
61. Gordon PV, Young ML, Marshall DD: Focal small bowel perforation: an
adverse eﬀect of early postnatal dexamethasone therapy in
extremely low birth weight infants. Journal of Perinatology 2001,
21(3):156–160.
62. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D: Hormone
replacement therapy and endometrial cancer risk: a meta-analysis.
Obstetrics and Gynecology 1995, 85(2):304–313.
63. Graham GD: Tissue plasminogen activator for acute ischemic stroke
in clinical practice: a meta-analysis of safety data. Stroke 2003,
34(12):2847–2850.
64. Greenland S, Satterﬁeld MH, Lanes SF: Ameta-analysis to assess the
incidence of adverse eﬀects associated with the transdermal
nicotine patch. Drug Safety 1998, 18(4):297–308.
65. Grodstein F, Newcomb PA, Stampfer MJ: Postmenopausal hormone
therapy and the risk of colorectal cancer: a review and
meta-analysis. American Journal of Medicine 1999, 106(5):574–582.
66. Grossman E, Messerli FH: Eﬀect of calcium antagonists on plasma
norepinephrine levels, heart rate, and blood pressure. American
Journal of Cardiology 1997, 80(11):1453–1458.
67. Guise JM, Berlin M, McDonagh M, Osterweil P, Chan B, Helfand M: Safety
of vaginal birth after cesarean: a systematic review. Obstetrics and
Gynecology 2004, 103(3):420–429.
68. Gupta P, Sachdev HP: Safety of oral use of nimesulide in children:
systematic review of randomized controlled trials. Indian Pediatrics
2003, 40(6):518–531.
69. Hart RG, Benavente O, Pearce LA: Increased risk of intracranial
hemorrhage when aspirin is combined with warfarin: a
meta-analysis and hypothesis. Cerebrovascular Diseases 1999,
9(4):215–217.
70. Hauth JC, Goldenberg RL, Parker CR, Cutter GR, Cliver SP: Low-dose
aspirin: lack of associationwith an increase in abruptio placentae or
perinatal mortality. Obstetrics and Gynecology 1995, 85(6):1055–1058.
71. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic
stroke: a meta-analysis of randomized controlled trials. JAMA 1998,
280(22):1930–1935.
72. He´bert-Croteau N: Ameta-analysis of hormone replacement
therapy and colon cancer in women. Cancer Epidemiology, Biomarkers
& Prevention 1998, 7(8):653–659.
73. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in
patients receiving calcineurin inhibitors: a systematic review and
meta-analysis. American Journal of Transplantation 2004, 4(4):583–595.
74. Henk JM: Controlled trials of synchronous chemotherapy with
radiotherapy in head and neck cancer: overview of radiation
morbidity. Clinical Oncology 1997, 9(5):308–312.
75. Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL: Risk
of venous thromboembolism from oral contraceptives containing
gestodene and desogestrel versus levonorgestrel: a meta-analysis
and formal sensitivity analysis. Contraception 2001, 64(2):125–133.
76. Henry D, McGettigan P: Epidemiology overview of gastrointestinal
and renal toxicity of NSAIDs. International Journal of Clinical Practice
2003, 135(Supplement):43–49.
77. Hoes AW, Grobbee DE, Peet TM, Lubsen J: Do non-potassium sparing
diuretics increase the risk of sudden cardiac death in hypertensive
patients: recent evidence. Drugs 1994, 47(5):711–733.
78. Huang JQ, Sridhar S, Hunt RH: Gastrointestinal safety proﬁle of
nabumetone: a meta-analysis. American Journal of Medicine 1999,
107(6A):55S–61S.
79. Humphrey LL, Takano LMA, Chan BKS: Postmenopausal hormone
replacement therapy and cardiovascular disease [Systematic evidence
review no. 10]. Rockville, MD: Agency for Healthcare Research and
Quality; 2002.
80. Hwang BF, Jaakkola JJ:Water chlorination and birth defects: a
systematic review andmeta-analysis. Archives of Environmental
Health 2003, 58(2):83–91.
81. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolﬁni C, Bonati M:
Incidence of adverse drug reactions in paediatric in/out-patients: a
systematic review andmeta-analysis of prospective studies. British
Journal of Clinical Pharmacology 2001, 52(1):77–83.
82. Ismail AI, Bandekar RR: Fluoride supplements and ﬂuorosis: a
meta-analysis. Community Dentistry and Oral Epidemiology 1999,
27(1):48–56.
83. Ivanov R, Allen J, Calvin JE: The incidence of major morbidity in
critically ill patients managed with pulmonary artery catheters: a
meta-analysis. Critical Care Medicine 2000, 28(3):615–619.
84. Janowsky EC, Kupper LL, Hulka BS:Meta-analysis of the relation
between silicone breast implants and the risk of connective tissue
diseases. New England Journal of Medicine 2000, 342(11):781–790.
85. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inﬂammatory
drugs aﬀect blood pressure: a meta-analysis. Annals of Internal
Medicine 1994, 121(4):289–300.
86. Johnston SC, Colford JJM, Gress DR: Oral contraceptives and the risk
of subarachnoid hemorrhage: a meta-analysis. Neurology 1998,
51(2):411–418.
87. Jolles BM, Bogoch ER: Posterior versus lateral surgical approach for
total hip arthroplasty in adults with osteoarthritis. Cochrane
Database of Systematic Reviews 2006
doi:10.1002/14651858.CD003828.pub3. Issue 3(Art. No.: CD003828).
88. Jones G, Riley M, Couper D, Dwyer T:Water ﬂuoridation, bonemass
and fracture: a quantitative overview of the literature. Australian
and New Zealand Journal of Public Health 1999, 23(1):34–40.
89. Jonker-Pool: Sexual functioning after treatment for testicular
cancer: review andmeta-analysis of 36 empirical studies between
1975–2000. Archives of Sexual Behavior 2001, 30(1):55–74.
90. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA: The safety
proﬁle of nonprescription ibuprofen in multiple-dose use: a
meta-analysis. Journal of Clinical Pharmacology 1999, 39(5):520–532.
91. Kemmeren JM, Algra A, Grobbee DE: Third generation oral
contraceptives and risk of venous thrombosis: meta-analysis. BMJ
2001, 323(7305):131–134.
92. Khader YS, Rice J, John L, Abueita O: Oral contraceptives use and the
risk of myocardial infarction: a meta-analysis. Contraception 2003,
68(1):11–17.
93. Ko DT, Hebert PR, Coﬀey CS, Sedrakyan A, Curtis JP, Krumholz HM:
Beta-blocker therapy and symptoms of depression, fatigue, and
sexual dysfunction. JAMA 2002, 288(3):351–357.
94. Ko DT, Hebert PR, Coﬀey CS, Curtis JP, Foody JM, Sedrakyan A, Krumholz
HM: Adverse eﬀects of beta-blocker therapy for patients with heart
failure: a quality overview of randomized trials. Archives of Internal
Medicine 2004, 164(13):1389–1394.
95. Kongnyuy EJ, Norman RJ, Flight IHK, Rees MCP: Oestrogen and
progestogen hormone replacement therapy for peri-menopausal
and post-menopausal women: weight and body fat distribution.
Cochrane Database of Systematic Reviews 1999
doi:10.1002/14651858.CD001018. Issue 3(Art. No.: CD001018).
96. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G: Aspirin
consumption during the ﬁrst trimester of pregnancy and
congenital anomalies: a meta-analysis. American Journal of Obstetrics
and Gynecology 2002, 187(6):1623–1630.
97. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug
reactions in hospitalized patients: a meta-analysis of prospective
studies. JAMA 1998, 279(15):1200–1205.
98. LeBlanc ES, Janowsky J, Chan BK, Nelson HD: Hormone replacement
therapy and cognition: systematic review andmeta-analysis. JAMA
2001, 285(11):1489–1499.
99. Lee TM, Yip JT, Jones-Gotman M:Memory deﬁcits after resection
from left or right anterior temporal lobe in humans: a
meta-analytic review. Epilepsia 2002, 43(3):283–291.
100. Lee A, Cooper MC, Craig JC, Knight JF, Keneally JP: Eﬀects of
nonsteroidal anti-inﬂammatory drugs on postoperative renal
function in adults with normal renal function. Cochrane Database of
Systematic Reviews 2004 doi:10.1002/14651858.CD002765. Issue 2(Art
No.: CD002765).
101. Leipzig RM, Cumming RG, Tinetti ME: Drugs and falls in older people:
a systematic review andmeta-analysis. I. Psychotropic drugs.
Journal of the American Geriatrics Society 1999, 47(1):30–39.
102. Leipzig RM, Cumming RG, Tinetti ME: Drugs and falls in older people:
a systematic review andmeta-analysis. II. Cardiac and analgesic
drugs. Journal of the American Geriatrics Society 1999, 47(1):40–50.
103. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H:
Hormone replacement therapy in postmenopausal women:
endometrial hyperplasia and irregular bleeding. Cochrane Database
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 12 of 14
http://www.biomedcentral.com/1471-2288/12/64
of Systematic Reviews 2004 doi:10.1002/14651858.CD000402. Issue
3(Art. No.: CD000402).
104. Lipworth BJ: Systemic adverse eﬀects of inhaled corticosteroid
therapy: a systematic review andmeta-analysis. Archives of Internal
Medicine 1999, 159(9):941–955.
105. Liu EH, Sia AT: Rates of Caesarean section and instrumental vaginal
delivery in nulliparous women after low concentration epidural
infusions or opioid analgesia: systematic review. BMJ 2004,
328(7453):1410–1412.
106. Loke YK, Derry S, Pritchard-Copley A: Appetite suppressants and
valvular heart disease: a systematic review. BMC Clinical
Pharmacology 2002, 2:6.
107. MacLennan SC, MacLennan AH, Ryan P: Colorectal cancer and
oestrogen replacement therapy: a meta-analysis of
epidemiological studies.Medical Journal of Australia 1995,
162(9):491–493.
108. Marcolongo R, Frediani B, Biasi G, Minari C, Barreca C: Ameta-analysis
of the tolerability of amtolmetin guacil, a novel, eﬀective
nonsteroidal anti-inﬂammatory drug, compared with established
agents. Clinical Drug Investigation 1999, 17(2):89–96.
109. Mardirosoﬀ C, Dumont L, Boulvain M, Tramer MR: Fetal bradycardia
due to intrathecal opioids for labour analgesia: a systematic
review. BJOG: an International Journal of Obstetrics and Gynaecology
2002, 109(3):274–281.
110. McAlister FA, Clark HD, Wells PS, Laupacis A: Perioperative allogeneic
blood transfusion does not cause adverse sequelae in patients
with cancer: a meta-analysis of unconfounded studies. British
Journal of Surgery 1998, 85(2):171–178.
111. Mehta SR, Eikelboom JW, Yusuf S: Risk of intracranial haemorrhage
with bolus versus infusion thrombolytic therapy: a meta-analysis.
Lancet 2000, 356(9228):449–454.
112. Miller J, Chan BK, Nelson H: Hormone replacement therapy and risk of
venous thromboembolism. [Systematic evidence review no. 11]. Rockville,
MD: Agency for Healthcare Research and Quality; 2002.
113. Moiniche S, Romsing J, Dahl JB, Tramer MR: Nonsteroidal
antiinﬂammatory drugs and the risk of operative site bleeding
after tonsillectomy: a quantitative systematic review. Anesthesia
and Analgesia 2003, 96(1):68–77.
114. Mol BW, AnkumWM, Bossuyt PM, Van der Veen, F: Contraception and
the risk of ectopic pregnancy: a meta-analysis. Contraception 1995,
52(6):337–341.
115. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH:
Cholesterol reduction and non-illness mortality: meta-analysis of
randomised clinical trials. BMJ 2000, 322(7277):11–15.
116. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S: Adverse events
in coronary artery bypass graft (CABG) trials: a systematic review
and analysis. Heart 2003, 89(7):767–772.
117. Nanda K, Bastian LA, Hasselblad V, Simel DL: Hormone replacement
therapy and the risk of colorectal cancer: a meta-analysis. Obstetrics
and Gynecology 1999, 93(5 Part 2 Supplement S):880–888.
118. Nazareth I, Lewin J, King M: Sexual dysfunction after treatment for
testicular cancer: a systematic review. Journal of Psychosomatic
Research 2001, 51(6):735–743.
119. O’Connell D, Robertson J, Henry D, Gillespie W: A systematic review of
the skeletal eﬀects of estrogen therapy in postmenopausal women.
II. An assessment of treatment eﬀects. Climacteric 1998, 1(2):112–123.
120. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA,
Shekelle P: Ametaanalysis of severe upper gastrointestinal
complications of nonsteroidal antiinﬂammatory drugs. Journal of
Rheumatology 2002, 29(4):804–812.
121. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA,
Shekelle PG:Meta-analysis of dyspepsia and nonsteroidal
antiinﬂammatory drugs. Arthritis and Rheumatism 2003, 49(4):508–518.
122. Oger E, Scarabin PY: Assessment of the risk for venous
thromboembolism among users of hormone replacement therapy.
Drugs and Aging 1999, 14(1):55–61.
123. Olsen O:Meta-analysis of the safety of home birth. Birth 1997,
24(1):4–13.
124. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L,
Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat
D, Nulman I, Einarson TR, Koren G: Birth defects after maternal
exposure to corticosteroids: prospective cohort study and
meta-analysis of epidemiological studies. Teratology 2000,
62(6):385–392.
125. Pfahlberg A, Hassan K, Wille L, Lausen B, Gefeller O: Systematic review
of case-control studies: oral contraceptives show no eﬀect on
melanoma risk. Public Health Reviews 1997, 25(3–4):309–315.
126. Pladevall-Vila M, Delclos GL, Varas C, Guyer H, Brugues-Tarradellas J,
Anglada-Arisa A: Controversy of oral contraceptives and risk of
rheumatoid arthritis: meta-analysis of conﬂicting studies and
review of conﬂicting meta-analyses with special emphasis on
analysis of heterogeneity. American Journal of Epidemiology 1996,
144(1):1–14.
127. Raaijmakers E, Engelen AM: Is sensorineural hearing loss a possible
side eﬀect of nasopharyngeal and parotid irradiation: a systematic
review of the literature. Radiotherapy and Oncology 2002, 65(1):1–7.
128. Ray JG, O’Brien TE, Chan WS: Preconception care and the risk of
congenital anomalies in the oﬀspring of women with diabetes
mellitus: a meta-analysis. QJM: An International Journal of Medicine
2001, 94(8):435–444.
129. Reid FD, Mercer PM, Harrison M, Bates T: Cholecystectomy as a risk
factor for colorectal cancer: a meta-analysis. Scandinavian Journal of
Gastroenterology 1996, 31(2):160–169.
130. Reynolds F, Sharma SK, Seed PT: Analgesia in labour and fetal
acid-base balance: a meta-analysis comparing epidural with
systemic opioid analgesia. BJOG: an International Journal of Obstetrics
and Gynaecology 2002, 109(12):1344–1353.
131. Robinson JW, Dufour MS, Fung TS: Erectile functioning of men
treated for prostate carcinoma. Cancer 1997, 79(3):538–544.
132. Ross SD, Kupelnick B, Kumashiro M, Arellano FM, Mohanty N, Allen IE:
Risk of serious adverse events in hypertensive patients receiving
isradipine: a meta-analysis. Journal of Human Hypertension 1997,
11(11):743–751.
133. Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L: Discontinuation
of antihypertensive drugs due to adverse events: a systematic
review andmeta-analysis. Pharmacotherapy 2001, 21(8):940–953.
134. Rothwell PM, Slattery J, Warlow CP: A systematic comparison of the
risks of stroke and death due to carotid endarterectomy for
symptomatic and asymptomatic stenosis. Stroke 1996, 27(2):266–269.
135. Rothwell PM, Slattery J, Warlow CP: A systematic review of the risks of
stroke and death due to endarterectomy for symptomatic carotid
stenosis. Stroke 1996, 27(2):260–265.
136. Ruesch S, Walder B, Tramer MR: Complications of central venous
catheters. Internal jugular versus subclavian access: a systematic
review. Critical Care Medicine 2002, 30(2):454–460.
137. Rutschmann OT, McCrory DC, Matchar DB: Immunization andMS: a
summary of published evidence and recommendations. Neurology
2002, 59(12):1837–1843.
138. Sachdev M, Miller WC, Ryan T, Jolis JG: Eﬀect of fenﬂuramine-
derivative diet pills on cardiac valves: a meta-analysis of
observational studies. American Heart Journal 2002, 144(6):1065–1073.
139. Safdar N, Said A, Gangnon RE, Maki DG: Risk of hemolytic uremic
syndrome after antibiotic treatment of Escherichia coli 0157:H7
enteritis: a meta-analysis. JAMA 2002, 288(8):996–1000.
140. Sagsveen M, Farmer JE, Prentice A, Breeze A: Gonadotrophin-releasing
hormone analogues for endometriosis: bone mineral density.
Cochrane Database of Systematic Reviews 2003
doi:10.1002/14651858.CD001297. Issue 4(Art. No.: CD001297).
141. Sakai H, Hayashi K, Origasa H, Kusunoki T: An application of
meta-analysis techniques in the evaluation of adverse experiences
with antihypertensive agents. Pharmacoepidemiology and Drug Safety
1999, 8(3):169–177.
142. Salpeter SR, Ormiston TM, Salpeter EE, Wood-Baker R: Cardioselective
beta-blockers for reversible airway disease. Cochrane Database of
Systematic Reviews 2002 doi:10.1002/14651858.CD002992. Issue 4(Art.
No.: CD002992).
143. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and
nonfatal lactic acidosis with metformin use in type 2 diabetes
mellitus. Archives of Internal Medicine 2003, 163(21):2594–2602.
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 13 of 14
http://www.biomedcentral.com/1471-2288/12/64
144. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE:Mortality
associated with hormone replacement therapy in younger and
older women: a meta-analysis. Journal of General Internal Medicine
2004, 19(7):791–804.
145. Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective beta-blockers
for chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews 2005 doi:10.1002/14651858.CD003566.pub2. Issue
4(Art. No.: CD003566).
146. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and
nonfatal lactic acidosis with metformin use in type 2 diabetes
mellitus. Cochrane Database of Systematic Reviews 2006
doi:10.1002/14651858.CD002967.pub2. Issue 1(Art. No.: CD002967).
147. Schaumberg DA, Dana MR, Christen WG, Glynn RJ: A systematic
overview of the incidence of posterior capsule opaciﬁcation.
Ophthalmology 1998, 105(7):1213–1221.
148. Schoenfeld P: Gastrointestinal safety proﬁle of meloxicam: a
meta-analysis and systematic review of randomized controlled
trials. American Journal of Medicine 1999, 107(6A):48S–54S.
149. Serebruany VL, Malinin AI, Eisert RM, Sane DC: Risk of bleeding
complications with antiplatelet agents: meta-analysis of 338,191
patients enrolled in 50 randomized controlled trials. American
Journal of Hematology 2004, 75(1):40–47.
150. Seto A, Einarson T, Koren G: Pregnancy outcome following ﬁrst
trimester exposure to antihistamines: meta-analysis. American
Journal of Perinatology 1997, 14(3):119–124.
151. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer
M, Franceschi S, Beral V: Cervical cancer and use of hormonal
contraceptives: a systematic review. Lancet 2003,
361(9364):1159–1167.
152. Sneyd JR, Carr A, Byrom WD, Bilski AJ: Ameta-analysis of nausea and
vomiting followingmaintenance of anaesthesia with propofol or
inhalational agents. European Journal of Anaesthesiology 1998,
15(4):433–445.
153. Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Luo D,
Ross SD, Chalmers TC: Safety of nifedipine in patients with
hypertension: a meta-analysis. Hypertension 1997, 30(1 Part 1):7–14.
154. Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Cory D,
Luo D, Ross SD, Chalmers TC: Safety of nifedipine in angina pectoris:
a meta-analysis. Hypertension 1999, 33(1):24–31.
155. Torgerson DJ, Bell-Syer SEM: Hormone replacement therapy and
prevention of nonvertebral fractures: a meta-analysis of
randomized trials. JAMA 2001, 285(22):2891–2897.
156. Torgerson DJ, Bell-Syer SEM: Hormone replacement therapy and
prevention of vertebral fractures: a meta-analysis of randomised
trials. BMCMusculoskeletal Disorders 2001, 2:7.
157. Torvaldsen S, Roberts CL, Bell JC, Raynes-Greenow CH: Discontinuation
of epidural analgesia late in labour for reducing the adverse
delivery outcomes associated with epidural analgesia. Cochrane
Database of Systematic Reviews 2004
doi:10.1002/14651858.CD004457.pub2. Issue 4(Art. No.: CD004457).
158. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ: Quantitative
estimation of rare adverse events which follow a biological
progression: a newmodel applied to chronic NSAID use. Pain 2000,
85(1–2):169–182.
159. Trindade E, Menon D, Topfer LA, Coloma C: Adverse eﬀects associated
with selective serotonin reuptake inhibitors and tricyclic
antidepressants: a meta-analysis. CanadianMedical Association
Journal 1998, 159(10):1245–1252.
160. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY: Eﬀects on
bonemass of long term treatment with thyroid hormones: a
meta-analysis. Journal of Clinical Endocrinology andMetabolism 1996,
81(12):4278–4289.
161. Vamvakas EC: Perioperative blood transfusion and cancer
recurrence: meta-analysis for explanation. Transfusion 1995,
35(9):760–768.
162. Vamvakas EC:Meta-analysis of randomized controlled trials
investigating the risk of postoperative infection in association with
white blood cell-containing allogeneic blood transfusion: the
eﬀects of the type of transfused red blood cell product and
surgical setting. TransfusionMedicine Reviews 2002, 16(4):304–314.
163. Vamvakas EC:WBC-containing allogeneic blood transfusion and
mortality: a meta-analysis of randomized controlled trials.
Transfusion 2003, 43(7):963–973.
164. Vercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA, De Broe, M E:
Ameta-analysis andmorphological review of
cyclosporine-induced nephrotoxicity in auto-immune diseases.
Kidney International 1998, 54(2):536–545.
165. Verhoeven AC, Boers M: Limited bone loss due to corticosteroids: a
systematic review of prospective studies in rheumatoid arthritis
and other diseases. Journal of Rheumatology 1997, 24(8):1495–1503.
166. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA: Fall
in mean arterial pressure and fetal growth restriction in pregnancy
hypertension: a meta-analysis. Lancet 2000, 355(9198):87–92.
167. Vorperian VR, Havighurst TC, Miller S, January CT: Adverse eﬀects of
low dose amiodarone: a meta-analysis. Journal of the American
College of Cardiology 1997, 30(3):791–798.
168. Warltier DCE, Marret E, Flahault A, Samama CM, Bonnet F: Eﬀects of
postoperative, nonsteroidal, antiinﬂammatory drugs on bleeding
risk after tonsillectomy: meta-analysis of randomized, controlled
trials. Anesthesiology 2003, 98(6):1497–1502.
169. Waterman EJ, Magee LA, Lim KI, Skoll A, Rurak D, von Dadelszen P: Do
commonly used oral antihypertensives alter fetal or neonatal heart
rate characteristics: a systematic review. Hypertension in Pregnancy
2004, 23(2):155–169.
170. Wehling M:Meta-analysis of ﬂecainide safety in patients with
supraventricular arrhythmias. Arzneimittel-Forschung Drug Research
2002, 52(7):507–514.
171. Wiﬀen P, Gill M, Edwards J, Moore A: Adverse drug reactions in
hospital patients: a systematic review of the prospective and
retrospective studies. Bandolier Extra 2002, 101:4.
172. Wilson K, Mottram P: A comparison of side eﬀects of selective
serotonin reuptake inhibitors and tricyclic antidepressants in older
depressed patients: a meta-analysis. International Journal of Geriatric
Psychiatry 2004, 19(8):754–762.
173. Xiong X, Buekens P, Wollast E: IUD use and the risk of ectopic
pregnancy: a meta-analysis of case-control studies. Contraception
1995, 52(1):23–34.
174. Yaﬀe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in
postmenopausal women: eﬀects on cognitive function and
dementia. JAMA 1998, 279(9):688–695.
175. Zaric DDZ, Christiansen CCC, Pace NL, Punjasawadwong Y: Transient
neurologic symptoms (TNS) following spinal anaesthesia with
lidocaine versus other local anaesthetics. Cochrane Database of
Systematic Reviews 2005 doi:10.1002/14651858.CD003006.pub2. Issue
4(Art. No.: CD003006).
176. Mantel N, Haenszel W: Statistical aspects of the analysis of data from
retrospective studies of disease. Journal of the National Cancer
Institute 1959, 22(4):719–748.
177. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and
after myocardial infarction: an overview of the randomized trials.
Progress in Cardiovascular Diseases 1985, 27(5):353–371.
178. DerSimonian R, Laird N:Meta-analysis in clinical trials. Controlled
clinical trials 1986, 7(3):177–188.
179. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315(7109):629–634.
180. Begg CB, Mazumdar M: Operating characteristics of a rank
correlation test for publication bias. Biometrics 1994,
50(4):1088–1101.
181. Duval S, Tweedie R: Trim and ﬁll: A simple funnel-plot-basedmethod
of testing and adjusting for publication bias in meta-analysis.
Biometrics 2000, 56(2):455–463.
182. Higgins JPT, Thompson SG: Quantifying heterogeneity in a
meta-analysis. Statistics in Medicine 2002, 21(11):1539–1558.
183. Higgins JPT, Thompson SG, Deeks JJ, Altman DG:Measuring
inconsistency in meta-analyses. BMJ 2003, 327(7414):557–560.
184. Takkouche B, Cadarso-Sua´rez C, Spiegelman D: Evaluation of old and
new tests of heterogeneity in epidemiologic meta-analysis.
American Journal of Epidemiology 1999, 150(2):206–215.
185. Berlin JA, Laird NM, Sacks HS, Chalmers TC: A comparison of statistical
methods for combining event rates from clinical trials. Statistics in
Medicine 1989, 8(2):141–151.
Warren et al. BMCMedical ResearchMethodology 2012, 12:64 Page 14 of 14
http://www.biomedcentral.com/1471-2288/12/64
186. Nissen S, Wolski K: Eﬀect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. New England
Journal of Medicine 2007, 356(24):2457–2471.
187. Diamond GA, Box L, Kaul S: Uncertain eﬀects of rosiglitazone on the
risk for myocardial infarction and cardiovascular death. Annals of
Internal Medicine 2007, 147(8):578–581.
188. Bracken MB: Rosiglitazone and cardiovascular risk. New England
Journal of Medicine 2007, 357(9):937–938.
189. Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S,
Semigran M, Koch G: A retrospective evaluation of congestive heart
failure andmyocardial ischemia events in 14 237 patients with
type 2 diabetes mellitus enrolled in 42 short-term, double-blind,
randomized clinical studies with rosiglitazone.
Pharmacoepidemiology and Drug Safety 2008, 17(8):769–781.
190. Nissen SE, Wolski K: Rosiglitazone revisited: an updated
meta-analysis of risk for myocardial infarction and cardiovascular
mortality. Archives of Internal Medicine 2010, 170(14):1191–1201.
191. Sweeting MJ, Sutton AJ, Lambert PC:What to add to nothing? Use
and avoidance of continuity corrections in meta-analysis of sparse
data. Statistics in Medicine 2004, 23(9):1351–1375.
192. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR:Much ado about nothing:
a comparison of the performance of meta-analytical methods with
rare events. Statistics in Medicine 2007, 26(1):53–77.
193. Ioannidis JPA, Trikalinos TA: The appropriateness of asymmetry tests
for publication bias in meta-analyses: a large survey. Canadian
Medical Association Journal 2007, 176(8):1091–1096.
194. Prevost TC, Abrams KR, Jones DR: Hierarchical models in generalized
synthesis of evidence: an example based on studies of breast
cancer screening. Statistics in Medicine 2000, 19(24):3359–3376.
195. Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG: Bias modelling
in evidence synthesis. Journal of the Royal Statistical Society Series A -
Statistics in Society 2009, 172(1):21–47.
196. Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC:Models for
potentially biased evidence in meta-analysis using empirically
based priors. Journal of the Royal Statistical Society Series A - Statistics in
Society 2009, 172(1):119–136.
197. Carlin JB:Meta-analysis for 2× 2 tables - a Bayesian approach.
Statistics in Medicine 1992, 11(2):141–158.
198. Ashby D, Hutton JL, McGee MA: Simple Bayesian analyses for
case-control studies in cancer epidemiology. Statistician 1993,
42(4):385–397.
199. Ashby D, Hutton JL: Bayesian epidemiology. New York, NY, USA; 1996.
200. Sutton AJ, Abrams KR: Bayesian methods in meta-analysis and
evidence synthesis. Statistical Methods in Medical Research 2001,
10(4):277–303.
201. Spiegelhalter D, Abrams K, Myles J: Bayesian approaches to clinical trials
and healthcare evaluation. Chichester, UK: John Wiley & Sons; 2004.
202. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR: How vague is
vague? A simulation study of the impact of the use of vague prior
distributions in MCMC usingWinBUGS. Statistics in Medicine 2005,
24(15):2401–2428.
203. Warren FC: An exploration of evidence synthesis methods for
adverse events. PhD thesis, University of Leicester, Department of
Health Sciences 2010.
doi:10.1186/1471-2288-12-64
Cite this article as: Warren et al.: Systematic review of methods used in
meta-analyses where a primary outcome is an adverse or unintended
event. BMCMedical ResearchMethodology 2012 12:64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
